|本期目录/Table of Contents|

[1]杨文静,王宁菊,陈冬梅.XRCC1-194突变、RRM1-37多态性与晚期NSCLC 患者含铂方案化疗效果的相关性研究[J].宁夏医科大学学报,2013,(01):13-17.
 YANG Wen-jing,WANG Ning-ju,CHEN Dong-mei.Mutation in XRCC1,Polymorphism in RRM1 and Efficacy of Platin-based Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer[J].Ningxia Medical University,2013,(01):13-17.
点击复制

XRCC1-194突变、RRM1-37多态性与晚期NSCLC 患者含铂方案化疗效果的相关性研究(PDF)
分享到:

《宁夏医科大学学报》[ISSN:1005-8486/CN:64-1029/R]

卷:
期数:
2013年01期
页码:
13-17
栏目:
论著
出版日期:
2013-01-20

文章信息/Info

Title:
Mutation in XRCC1,Polymorphism in RRM1 and Efficacy of Platin-based Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer
作者:
杨文静1 王宁菊2 陈冬梅3
1.宁夏医科大学,银川 750004; 2.宁夏医科大学总医院肿瘤医院肿瘤内科,银川 750004; 3.安徽省胸科医院肿瘤科,合肥 230022
Author(s):
YANG Wen-jing1 WANG Ning-ju2 CHEN Dong-mei3
1.Ningxia Med. Univ., Yinchuan 750004; 2.Dept. of Oncology, General Hospital of Ningxia Med. Univ.,Yinchuan 750004; 3.Dept. of Oncology,Anhui Chest Hospital,Hefei 230022
关键词:
XRCC1-194 RRM1-37 突变 多态性 非小细胞肺癌 铂类 疗效
Keywords:
XRCC1-194 RRM1-37 mutation gene polymorphism non-small cell lung cancer platinum
分类号:
R737.9
DOI:
-
文献标志码:
A
摘要:
目的 探讨XRCC1-194突变、RRM1-37多态性与含铂方案治疗晚期非小细胞肺癌(NSCLC)患者对疗效及生存的关系。方法 采用PCR-RFLP技术同时检测54例晚期NSCLC(ⅢB~Ⅳ期)患者及50例健康献血者XRCC1-194突变、RRM1-37基因型,分析其基因型频率与晚期NSCLC患者采用以铂类为基础方案化疗疗效及生存间的相关性。结果携带XRCC1Arg194Trp + Trp194Trp基因型的患者组化疗有效率为72.2%,高于携带野生型Arg194Arg基因型者(36.1%),χ2=6.268,P=0.012,前者的化疗效率是后者的3倍(OR=3.453,95% CI=1.361~8.764); Arg194Trp + Trp194Trp基因型患者中位生存期、1、2年生存率均优于携带野生型Arg194Arg基因型患者,但两组相比差异无统计学意义(χ2=0.265,P=0.607)。携带RRM137A/C、37CC基因型患者的化疗有效率分别为50.0%(11/22)、46.9%(15/32),两组间无统计学意义(χ2=0.051,P=0.821); 前组患者中位生存期、1、2年生存率与后组基因型患者相比,亦无统计学意义(χ2=0.627,P=0.357)。结论 化疗前对患者XRCC1-194进行突变检测,在一定程度上可以预测晚期NSCLC对铂类药物的敏感性。XRCC1-194突变、RRM1-37多态性与晚期NSCLC患者生存无明显相关性。
Abstract:
Objective To explore the relationship of mutation in XRCC1-194、polymorphism in RRM1-37 with efficacy and existence of platinum-based chemotherapy in patients with advanced non-small cell lung cancer. Methods PCR-RFLP and sequencing technique were used to detect XRCC1-194 Mutation, RRM1-37 polymorphisms in 54 cases with advanced NSCLC and 50 healthy controls. The association between the ERCC1,RRM1 gene polymorphism and efficacy of platinum-based chemotherapy in patients with advanced NSCLC was analyzed. Results In the XRCC1-194 gene,Arg194Trp+Trp194Trp genotype, the efficiency of chemotherapy patients was 72.2%, which was significantly higher than the Arg194Arg genotype(36.1%), OR=3.453, 95% CI=1.361~8.764, P=0.012. In the RRM1-37 gene promoter region, 37A/C and 37CC(Wild type)genotype, response rate in patients with chemotherapy was 46.9%(15/32), 50.0%(11/22)respectively(χ2 =0.051, P=0.821). Patients with advanced NSCLC carrying XRCC1 genotypes Arg194Trp+Trp194Trp showed no significantly higher 1- and 2-year median survival time, than patients the carrying Arg194Arg genotype(χ2=0.265, P=0.607). The median survival time, 1- and 2-year survival rates in advanced NSCLC patients had no significant difference between RRM1-37 genotypes carrying A/C and CC groups(χ2=0.627,P=0.357). Conclusion To a certain extent,XRCC1-194 genotyping in advanced NSCLC patients can predict the sensitivity to platinum drugs before chemotherapy. XRCC1-194 Mutation,RRM1-37 polymorphisms and advanced NSCLC patient survival showed no significant correlation.

参考文献/References:

[1] RosellR,Cecere F,SantarpiaM,et al. predicting the outcome of chemotherapy for lung cancer[J]. Curr Opin Pharmacol,2006,6:323-333.
[2] Rosellr,Cobom,Islad,et al. Phamcogenomics and gemciabine[J].Ann Oncol,2006,17(5): 13-16.
[3] Duffaud F,Therasse P.New guidelines to evaluate the response to teeatment in solid tumors [J].Bull Cancer,2000,87:881-886.
[4] Rosell R,Lord RV,Taron M,et al. DNA repair and cisplatin resistance in non-small-cell lung cancer[J]. Lung Cancer,2002,38: 217-227.
[5] 袁芃,缪小平,张雪梅,等.DNA损伤修复基因XRCC1和XPD遗传多态与晚期非小细胞肺癌对铂类药物的敏感性[J].中华肿瘤杂志,2006,28(3):196-199.
[6] Gurubhagavatula S,Liu G,Park S,et al. XPD and XRCC1genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemo-therapy[J].J Clin Oncol,2004,22(13):2594-2601.
[7] 邱立新,钱晓萍,刘宝瑞,等.XRCC1基因多态性与晚期非小细胞肺癌铂类药化疗敏感性的关系[J].现代肿瘤医学,2009,17(2):263-265.
[8] Lunn RM,Langlois RG,Hsieh LL,et al.XRCC1 polymorphisms:effects on aflatoxin B-DNA adducts and glycophorin A variant frequency[J]. Cancer Res,1999,59(11): 2557-2559.
[9] Gajecka M,Rydzanicz M,Jaskula-Sztul R,et al. Reduced DNA repair capacity in laryngeal cancer subjects. A comparison of phenotypic and genotypic results[J]. Adv Otorhinolaryngol, 2005,62(1):25-37.
[10] 宋德刚,刘杰,王哲海,等.XRCC1单核苷酸多态性预测晚期NSCLC铂类药物化疗的敏感性[J].肿瘤防治研究,2007,34(11):845-847.
[11] 应荣彪,陈明聪,瞿海江,等.XRCC1基因多态性预测晚期NSCLC对铂类药物的化疗敏感性[J].中高等医学教育,2010,4:142-143.
[12] Gurubhagavatula S,Liu G,Park S,et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy[J]. Journal of Clinical Oncology,2004,22(13):2594-2601.
[13] Kim SO,Jeong JY,Kim MR,et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene[J]. Clin Cancer Res,2008,14(10):3083-3088.
[14] Isla D,Sarries C,Rosell R. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non small cell lung cancer cancer[J]. Ann Oncol,2004,15(8):1194-1203.
[15] 苏彤,赵立,常文军,等.ERCC1、XPD和BRCA1基因多态与晚期非小细胞肺癌患者铂类药物化疗效果的相关性[J].第二军医大学学报,2010,31(2):117-122.

相似文献/References:

[1]闫蓉,贺晓慧.育精汤治疗男性不育症的疗效观察[J].宁夏医科大学学报,2009,(05):687.
[2]赵晓峰,马瑞霞.突发性耳聋疗效与相关因素分析[J].宁夏医科大学学报,2010,(09):982.
 ZHAO Xiao-feng,MA Rui-xia.Analysis of Prognosis and Related Factors for Sudden Deafness[J].Ningxia Medical University,2010,(01):982.
[3]钟慧军,彭 亮,朱永生,等.脑源性神经营养因子基因3个SNPs位点 与精神分裂症的相关性[J].宁夏医科大学学报,2010,(09):953.
 ZHONG Hui-jun,PENG Liang,ZHU Yong-sheng,et al.Association between Polymorphisms of the Brain-derived Neurotrophic factor Gene and Schizophrenia[J].Ningxia Medical University,2010,(01):953.
[4]墙 华,杨 丽,胡小平,等.线粒体DNA np16189和np16223多态性与 乳腺癌相关性研究[J].宁夏医科大学学报,2010,(08):849.
 QIANG Hua,YANG Li,HU Xiao-ping,et al.The Association between mtDNA np16189, np16223 Polymorphisms and Breast Cancer[J].Ningxia Medical University,2010,(01):849.
[5]许红霞,张毓洪,高 岭,等.瘦素基因启动子G-2548A多态性与青年高血压的相关性研究[J].宁夏医科大学学报,2010,(05):603.
 XU Hong-xia,ZHANG Yu-hong,GAO Ling,et al.Association between G-2548A Polymorphism of Promoter of theLeptin Gene and Young Hypertension[J].Ningxia Medical University,2010,(01):603.
[6]师志云,杨宝珍,王立斌,等.CTLA-4基因的多态性与自身免疫性甲状腺病的相关性研究[J].宁夏医科大学学报,2010,(03):330.
 SHI Zhi-yun,YANG Bao-zhen,WANG Li-bin,et al.Study of the A/G(49)Polymorphism of CTLA-4 Gene Exon 1 in Autoimmune Thyroid Diseases[J].Ningxia Medical University,2010,(01):330.
[7]陈丽君,马蕊梅,许 旺,等.宁夏回汉族环氧化酶2-1195G>A的分析[J].宁夏医科大学学报,2012,(11):1110.
 CHEN Li-jun,MA Rui-mei,XU Wang,et al.The Frequency of COX-2-1195G>A Polymorphism in Ningxia Population[J].Ningxia Medical University,2012,(01):1110.
[8]张 鑫,杜 勇,李 海,等.宁夏地区散发性大肠癌APC基因突变的研究[J].宁夏医科大学学报,2012,(07):660.
 ZHANG Xin,DU Yong,LI Hai,et al.Analysis of APC Gene Mutations in Sporadic Patients with Colorectal Cancer in Ningxia[J].Ningxia Medical University,2012,(01):660.
[9]崔丽萍,张 锦,尹 梅,等.血清骨桥蛋白水平与非小细胞肺癌预后的相关性[J].宁夏医科大学学报,2012,(03):248.
 CUI Li-ping,ZHANG Jin,YIN Mei,et al.Relationship between Serum Osteopontin Levels and Prognosisin Non-small Cell Lung Cancer[J].Ningxia Medical University,2012,(01):248.
[10]党占翠,宋琦如,杨文海,等.IL-1β-511位点基因多态性与宁夏地区煤工尘肺的关系[J].宁夏医科大学学报,2012,(01):52.
 DANG Zhan-cui,SONG Qi-ru,YANG Wen-hai,et al.Relationship Between Interleukin-1β(511C/T)Gene Polymorphisms and Coal Worker's Pneumoconiosis in Ningxia[J].Ningxia Medical University,2012,(01):52.

备注/Memo

备注/Memo:
收稿日期:2012-05-24 基金项目:宁夏科技计划项目 作者简介:杨文静,在读硕士研究生。E-mail: wenjing870425@163.com 通信作者:王宁菊,教授,硕士研究生导师。E-mail:doctorning@163.com
更新日期/Last Update: 2013-01-20